Join over 25,000 investors, academics and operators who receive the latest news on the psychedelic science and healthcare industry. Straight to your inbox once a week.
Awakn Life Sciences lists on the NEO Exchange; examining psychedelic revenue opportunities within tight regulations; IPOs build momentum as atai Life Sciences goes public. Read more in Issue 34 of The Psychedelics Newsletter.
Examining the business impact of North American psychedelic drug regulations; atai Life Sciences targets US$2.3 billion IPO valuation; and democrats introduce a bill to end the War on Drugs. Read more in Issue 33 of The Psychedelics Newsletter.
Three new speakers for the PSYCH Investor Summit; MindMed CEO steps down; study begins on psychedelics as a treatment for COVID distress. Read more in Issue 32 of The Psychedelics Newsletter.
For-profit or non-profit? That is the ($100-billion) question. Rick Doblin and Christian Angermayer join the 7 July PSYCH Investor Summit: Research and Development to discuss the role of non and for-profit businesses in a can’t-miss conversation. Read more in Issue 31 of The Psychedelics Newsletter.
Dr. Carl Hart on the impediment of prolonged research; Field Trip appoints former US Senate Majority Leader as Special Adviser and Cybin studies sublingual psilocybin for major depressive disorder. Read more in Issue 30 of The Psychedelics Newsletter.
Deepak Chopra partners with MindMed, treating Parkinson’s with ketamine and the case for Class A drugs for depression. Read more in Issue 29 of The Psychedelics Newsletter.
Exploring the psychedelics landscape in Asia, psychedelic treatments for Alzheimer’s and using AI to identify psychedelic drugs for depression. Read more in Issue 28 of The Psychedelics Newsletter.
Announcing the next PSYCH Investor Summit: Research & Development, MindMed hits the NASDAQ and exploring the use of psychedelics to treat addiction. Read more in Issue 26 of The Psychedelics Newsletter.
Rick Doblin on MAPS 35 years, the future of the psychedelics industry and kicking off the PSYCH Investor Summit: Europe & Asia. Read more in Issue 25 of The Psychedelics Newsletter.
Exploring psychedelics apps, Awakn Life Sciences’ new Digital unit and counting down to the PSYCH Investor Summit: Europe & Asia. Read more in Issue 24 of The Psychedelics Newsletter.
Exploring the potential to create ethical psychedelics companies, a DNA test to inform psychedelic therapies, and preparing for the PSYCH Investor Summit: Europe and Asia. Read more in Issue 23 of The Psychedelics Newsletter.
Four companies added to the world’s largest psychedelics exchange and adding Field Trip Health to the PSYCH Investor Summit: Europe and Asia. Learn more in Issue 22 of The Psychedelics Newsletter.
Join over 25,000 investors, academics and operators who receive the latest news on the psychedelic science and healthcare industry. Straight to your inbox once a week.
Subscribe to the Psychedelics Newsletter
Join over 25,000 investors, academics and operators who receive the latest news on the psychedelic science and healthcare industry. Straight to your inbox once a week.
